Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 15Neoplasm, Residual 2Myelodysplastic Syndromes 2Mastocytosis, Systemic 2Leukemia, Mast-Cell 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Congenital Abnormalities 1Aggression 1

Interventions

Cytarabine 2Cyclosporine 2Cyclophosphamide 2midostaurin 1fludarabine phosphate 1Whole-Body Irradiation 1Transplantation 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Miransertib 1Methotrexate 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Daunorubicin 1Cord Blood Stem Cell Transplantation 1Clofarabine 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Congenital Abnormalities × midostaurin × Clear all
NCT00093600 2020-12-19

PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Novartis

Phase 1 Completed
69 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡